• February 18, 2019
• 0

Roche has bagged NICE backing for Perjeta (pertuxumab) in the prevention of early-stage HER2-positive breast cancer from recurring after surgery, after three attempts. The new draft guidance permits Perjeta to be given...

• January 9, 2019
• 0

The National Institute for Health Care and Excellent (NICE) has rejected Novartis' migraine drug Aimovig (erenumab) as preventative treatment for migraine in draft guidelines. The news comes after Aimovig was...